This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The Galenica Group
Drug Names(s): PA-21, PA21, P-TOL (Japan)
Description: PA21 is an iron-based phosphate binder.
Deal Structure: In June 2010, Vifor announced that Fresenius Medical Care will become the commercial partner of PA21 in North America.
In September 2010, Vifor Pharma entered into an agreement with Kissei Pharmaceutical to develop and commercialise PA21 in Japan.
In December 2010, Fresenius Medical Care and Galenica announced the formation of a new renal pharmaceutical company (Vifor-Fresenius Medical Care Renal Pharma Ltd.) designed to develop and distribute on a worldwide basis products to treat iron deficiency anaemia and bone mineral metabolism for pre-dialysis and dialysis patients. The newly formed company extends existing agreements with Galenica.
Partners: Fresenius SE Kissei Pharmaceutical Co., Ltd
Additional information available to subscribers only: